Business Description
Alaunos Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US98973P1012
Description
Financial Strength
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 5.18 | |||||
Equity-to-Asset | 0.76 | |||||
Debt-to-Equity | 0.19 | |||||
Debt-to-EBITDA | -0.04 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | -161.81 | |||||
Beneish M-Score | 36.31 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -72.6 | |||||
3-Year EPS without NRI Growth Rate | -69.1 | |||||
3-Year FCF Growth Rate | -81.3 | |||||
3-Year Book Growth Rate | -64.3 |
Momentum Rank
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 58.76 | |||||
9-Day RSI | 44.8 | |||||
14-Day RSI | 41.27 | |||||
6-1 Month Momentum % | 23.77 | |||||
12-1 Month Momentum % | -76.67 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 4.22 | |||||
Quick Ratio | 4.22 | |||||
Cash Ratio | 3.1 | |||||
Days Sales Outstanding | 219 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -3.8 | |||||
Shareholder Yield % | 107.41 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Operating Margin % | -569860 | |||||
Net Margin % | -702800 | |||||
FCF Margin % | -606780 | |||||
ROE % | -159.84 | |||||
ROA % | -103.84 | |||||
ROIC % | -208.61 | |||||
ROC (Joel Greenblatt) % | -313.04 | |||||
ROCE % | -142.83 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 264 | |||||
PB Ratio | 3.38 | |||||
Price-to-Tangible-Book | 3.38 | |||||
EV-to-EBIT | -0.38 | |||||
EV-to-EBITDA | -0.4 | |||||
EV-to-Revenue | 2502.4 | |||||
EV-to-Forward-Revenue | 4293.85 | |||||
EV-to-FCF | -0.41 | |||||
Price-to-Net-Current-Asset-Value | 3.38 | |||||
Price-to-Net-Cash | 5.08 | |||||
Earnings Yield (Greenblatt) % | -263.16 | |||||
FCF Yield % | -143.56 |